Literature DB >> 14632969

Use of pharmacoeconomics in prescribing research. Part 5: modelling--beyond clinical trials.

D L Lang1, R Lopert, S R Hill.   

Abstract

This paper provides an overview of modelling in the economic evaluation of pharmaceuticals, reflecting the increasing use of models in analyses prepared for reimbursement applications to national and local drug formularies. The paper seeks to demystify the most commonly encountered modelling techniques (extrapolation, decision analysis, Markov modelling and Monte Carlo simulation), and to provide guidance in assessing the quality of submitted or published modelled economic evaluations.

Entities:  

Mesh:

Year:  2003        PMID: 14632969     DOI: 10.1046/j.1365-2710.2003.00458.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  4 in total

Review 1.  Sensitivity analysis in cost-effectiveness studies: from guidelines to practice.

Authors:  Rahul Jain; Michael Grabner; Eberechukwu Onukwugha
Journal:  Pharmacoeconomics       Date:  2011-04       Impact factor: 4.981

2.  Drugs for rare disorders.

Authors:  Serge Cremers; Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2017-06-27       Impact factor: 4.335

Review 3.  The generalisability of pharmacoeconomic studies: issues and challenges ahead.

Authors:  James M Mason; Anne R Mason
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany.

Authors:  Stefan Pscherer; Eva Susanne Dietrich; Franz-Werner Dippel; Aileen Rae Neilson
Journal:  Ger Med Sci       Date:  2010-08-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.